D. Cell-based GnRHR assay

DK David C Kem
HL Hongliang Li
XY Xichun Yu
EW Elizabeth Weedin
AR Anna C Reynolds
EF Elizabeth Forsythe
MB Marci Beel
HF Hayley Fischer
BH Brendon Hines
YG Yankai Guo
JD Jielin Deng
JL Jonathan T Liles
ZN Zachary Nuss
ME Myriam Elkosseifi
CA Christopher E Aston
HB Heather R Burks
LC LaTasha B Craig
ask Ask a question
Favorite

GnRHR-AAb activity in serum IgG was measured with a calcium flux assay using a Ready-to-Assay GnRHR-expressing Chem-1 cell line (Eurofins Bioanalytics, St Charles, MO), according to the manufacturer’s protocol. Briefly, Chem-1 cells were dispensed into a 96-well microplate and incubated for 24 hours. After the plate was washed with Hanks balanced salt solution supplemented with 20 mM HEPES and 2.5 mM probenecid at pH 7.4, Fluo-8 NW (AAT Bioquest, Sunnyvale, CA), Ca2+ dye-loading solution was added to each well and incubated for 1 hour. Serum IgG, GnRHR agonist GnRH, or leuprolide (Sigma-Aldrich) was then added in constant volumes. Calcium flux response was recorded every 20 seconds for 180 seconds on a Hidex Sense microplate reader (Hidex, Turku, Finland). All samples were tested in triplicate. Data are expressed as a percentage of buffer baseline fluorescence signal to normalize the individual values. A value of 100% of basal activity represents the activity associated with the presence of buffer alone. A value of 100% of basal activity represents the activity associated with the presence of buffer alone. The intra-assay coefficient of variation is 8.2% (N = 58) and the interassay coefficient of variation is 8.0% (N = 8). Serum IgG (10-150 μg/mL) was used to assess activity dosage responses. IgG was tested at 4 different concentrations (0, 50, 100, and 150 μg/mL) to determine an optimal concentration for study. In separate experiments, IgG (100 μg/mL) was added in the absence and presence of the GnRHR antagonist cetrorelix (10–7 M) (Thermo Fisher Scientific) to measure specific receptor activity for individual subjects. GnRH (10–9-10–6 M) in the absence and presence of serum IgG (100 μg/mL) was also tested to examine a possible allosteric effect of the PCOS IgG on the established GnRHR orthosteric ligand response.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A